Gynecological Endocrinology
Volume 39, 2023 - Issue 1
Research Article
Relugolix combination therapy in European women with symptomatic uterine fibroids: a subgroup analysis from the randomized phase 3 LIBERTY pivotal trials
Roberta Venturellaa Department of Clinical and Experimental Medicine, Unit of Obstetrics and Gynecology, Magna Graecia University of Catanzaro, Catanzaro, ItalyCorrespondence[email protected]
https://orcid.org/0000-0003-1359-770XView further author information
https://orcid.org/0000-0003-1359-770XView further author information, Tomasz Rechbergerb Second Department of Gynecology, Medical University of Lublin, Lublin, Polandhttps://orcid.org/0000-0003-4138-332XView further author information
https://orcid.org/0000-0003-4138-332XView further author information, , , , Viatcheslav G. Rakovf Research and Development, Myovant Sciences GmbH, Basel, Switzerlandhttps://orcid.org/0009-0004-0324-9239View further author information
https://orcid.org/0009-0004-0324-9239View further author information & Felice Petragliag Department of Experimental, Clinical and Biomedical Sciences, Obstetrics and Gynecology, University of Florence, Careggi University Hospital, Florence, Italyhttps://orcid.org/0000-0002-8851-625XView further author information
https://orcid.org/0000-0002-8851-625XView further author information show all